AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Atomwise vs Recursion Pharmaceuticals

VS
Atomwise official logo and brand icon

Atomwise

Enterprise
Visit WebsiteFull Review
Recursion Pharmaceuticals official logo and brand icon

Recursion Pharmaceuticals

Enterprise
Visit WebsiteFull Review

Verdict by Category

Detailed category analysis is not available for this comparison.
View Atomwise View Recursion Pharmaceuticals
Feature & Spec Matrix

Detailed Comparison26 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
Atomwise
Atomwise
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Pricing Model
EnterpriseAtomwise operates through enterprise partnership and co-development agreements — there is no self-serve access or published pricing. Collaboration types include: sponsored research agreements (pharma/biotech pays Atomwise to run AI-powered hit discovery campaigns), co-development partnerships (shared IP and milestone/royalty structures), and academic program access for universities through the ATOM initiative. New CEO Steve Worland is also steering Atomwise toward an internal proprietary drug pipeline, which will generate revenue through future licensing and partnering deals as candidates mature into preclinical and clinical stages. Contact Atomwise through atomwise.com for partnership and collaboration inquiries.
EnterpriseAI-enabled drug discovery and mapping (Recursion OS) — Custom biopharma enterprise partnership agreements only
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No free plan — enterprise and academic collaboration agreements via sales/partnership team
No self-serve access — enterprise pharma collaborations and data licensing via partnership team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Pharmaceutical and biotech R&D teams needing AI-powered virtual screening and hit discovery against novel, difficult, or undruggable disease targets at industrial scale
Major pharma companies and researchers needing AI-powered biology mapping, target discovery, and drug candidate generation at industrial scale through the Recursion OS platform
Enterprise & Scalability
Difference
Enterprise pharma collaboration agreements; 250+ partner network; custom research contracts with major pharmaceutical, agrochemical, and biotech companies; academic partnership program for universities including Harvard, Stanford, and Duke
NASDAQ listed (RXRX), $500M+ in pharma partnership milestones earned, enterprise collaboration agreements with Roche/Genentech and Sanofi, automated biology and chemistry labs at industrial scale in Salt Lake City and Oxford, and data licensing for external researchers
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
AtomNet — world's first deep CNN for structure-based drug discovery, screening 16B+ compounds in under 2 days
Supported
Supported
600+ unique disease targets tackled across oncology, CNS, infectious disease, and rare diseases
Difference
Atomwise Advantage
Not listed
185+ completed projects validated across diverse protein types including undruggable targets
Difference
Atomwise Advantage
Not listed
775+ collaborations with 250+ partners worldwide — pharma, biotech, agrochemical, and academic
Difference
Atomwise Advantage
Not listed
Foundation Model for molecular discovery — next-generation AI announced at TRANSONC 2026
Difference
Atomwise Advantage
Not listed
Proprietary pipeline of small-molecule drug candidates advancing into preclinical studies
Difference
Atomwise Advantage
Not listed
AIDDISON platform for structure-based hit discovery and lead optimization
Difference
Atomwise Advantage
Not listed
Co-development agreements with major pharma — Merck, and 4 of top 10 US pharmaceutical companies
Difference
Atomwise Advantage
Not listed
Academic ATOM program: collaborations with 40+ universities including Harvard, Stanford, and Duke
Difference
Atomwise Advantage
Not listed
Founded 2012 — pioneered deep learning in drug discovery; $226M+ total raised
Difference
Atomwise Advantage
Not listed
Industrial-scale automated labs in Salt Lake City and Oxford generating proprietary multimodal data
Difference
Not listed
Recursion Pharmaceuticals Advantage
REC-4881 for FAP — 53% polyp reduction in Phase 2, FDA registration discussions begun 2026
Difference
Not listed
Recursion Pharmaceuticals Advantage
REC-1245 (RBM39 degrader) in Phase 1/2 DAHLIA study for solid tumors
Difference
Not listed
Recursion Pharmaceuticals Advantage
REC-4539 (LSD1 inhibitor) — first patient dosed in Phase 1 ENLYGHT study 2026
Difference
Not listed
Recursion Pharmaceuticals Advantage
Sanofi partnership — $134M earned to date across 5 milestones
Difference
Not listed
Recursion Pharmaceuticals Advantage
Roche/Genentech Phenomaps — 1 trillion neuronal cells for neuroscience target discovery
Difference
Not listed
Recursion Pharmaceuticals Advantage
$500M+ in cumulative pharma partnership milestones earned to date
Difference
Not listed
Recursion Pharmaceuticals Advantage
Recursion Data — phenomics and biology maps licensed to external researchers and pharma
Difference
Not listed
Recursion Pharmaceuticals Advantage
NASDAQ: RXRX — founded 2013; $74.7M revenue in 2025; acquired Exscientia in 2024
Difference
Not listed
Recursion Pharmaceuticals Advantage
Atomwise icon

Atomwise Pros & Cons

Pros

  • Invented deep learning for structure-based drug discovery in 2012 — true pioneer in the field
  • AtomNet screens 16B+ compounds in under 2 days — fastest virtual screening at this scale
  • 775+ collaborations and 250+ partners — most validated partnership network in AI drug discovery
  • Tackles undruggable targets that traditional methods can't address
  • Strong academic program: 40+ universities including Harvard, Stanford, and Duke
  • New Foundation Model announced 2026 — next-generation AI for molecular discovery
  • $226M+ raised from DCVC, Khosla, Y Combinator, Tencent, B Capital, and Baidu

Cons

  • Early-stage company — no FDA-approved drugs from the platform yet
  • Shifting focus from platform licensing to proprietary pipeline adds execution risk
  • Smaller team (~100-250 employees) compared to larger AI drug discovery peers
  • Revenue still modest at $5-25M range — pre-commercial stage
  • Deep tech focus means long timelines before patient impact is realized
Recursion Pharmaceuticals icon

Recursion Pharmaceuticals Pros & Cons

Pros

  • $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
  • Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
  • Industrial-scale automated labs generate data no other company can replicate
  • Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
  • Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
  • Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
  • Cash runway guided into early 2028 — disciplined capital allocation

Cons

  • Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
  • Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
  • Acquired Exscientia in 2024 — integration complexity and added operational overhead
  • No approved drugs yet — clinical proof of concept still early stage
  • Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Recursion Pharmaceuticals vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Recursion Pharmaceuticals and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Tempus AI vs Atomwise Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Tempus AI and Atomwise in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Schrödinger vs Atomwise Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Schrödinger and Atomwise in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Atomwise vs Abridge Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Atomwise and Abridge in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare